Researcher
Patrick Neven
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Jan 2012 → Today
Projects
1 - 10 of 13
- Early folliculogenesis and ovarian aging in women with genetic predisposition to (breast)cancerFrom15 Jul 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Effectiveness of an eHealth self-management support program for persistent pain after breast cancer treatmentFrom1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- breastcancer and sexualityFrom25 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical, pathological and molecular characterization of invasive lobular carcinoma (ILC)From12 Aug 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Epidemiological study of relapse in breast, ovarian and cervical cancers.From1 Oct 2018 → 30 Sep 2021Funding: Nonprofit institution or equivalents
- Towards a better selection of systemic treatment for patients with ER-positive HER2-negative breast cancer: the use of prognostic and predictive markers in early and metastatic settingFrom1 May 2017 → 14 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Role of combined chemo- and immunotherapy in early breast cancerFrom1 Oct 2016 → 30 Sep 2020Funding: Nonprofit institution or equivalents
- Key biological processes involved in breast cancer invasion and metastases leading to residual disease after local therapy of breast tumors.From1 Jul 2014 → 30 Jun 2018Funding: Private funding of national origin - undefined
- Assessment of market access policies and instruments for oncology drugs.From1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
Publications
11 - 20 of 572
- Navigating next-generation HR+ /HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression(2023)
Authors: Patrick Neven, Sileny Han, Yannick Van Herck, Hans Wildiers
- Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer(2023)
Authors: Yentl Lambrechts, Abhishek Garg, Beppe Floris, Patrick Neven, Ines Nevelsteen, François Richard, Annouschka Laenen, Christine Desmedt, Hans Wildiers, Sigrid Hatse
Pages: 270 - 279 - Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes(2023)
Authors: Patrick Neven
Pages: S1256 - S1256 - Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer(2023)
Authors: Yentl Lambrechts, Abhishek Garg, Patrick Neven, Ines Nevelsteen, François Richard, Christine Desmedt, Hans Wildiers, Sigrid Hatse
Pages: 270 - 279 - A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2-early breast cancer (EBC): Final analysis from EMBER-2(2023)
Authors: Patrick Neven
Pages: S292 - S293 - Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features(2023)
Authors: Beppe Floris, Kristel Van Calsteren, Patrick Neven, Sileny Han, Daniela Annibali, Diether Lambrechts, Liesbeth Lenaerts, Frédéric Amant
Pages: 3729 - 3743 - Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer(2023)
Authors: Karen Van Baelen, Ha Linh Nguyen, François Richard, Maxim De Schepper, Tatjana Geukens, Sileny Han, Thaïs Baert, Hans Wildiers, Ann Smeets, Ines Nevelsteen, et al.
- Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors(2023)
Authors: Yentl Lambrechts, Sigrid Hatse, François Richard, Bram Boeckx, Beppe Floris, Christine Desmedt, Patrick Neven, Diether Lambrechts, Hans Wildiers
- Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant(2023)
Authors: Patrick Neven
- RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish Observational Cohort Study(2023)
Authors: Josephine Van Cauwenberge, Kristien Borremans, Sileny Han, Annouschka Laenen, Patrick Neven
Pages: 998 - 999